Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P09093
UPID:
CEL3A_HUMAN
Alternative names:
Elastase IIIA; Elastase-3A; Protease E
Alternative UPACC:
P09093; B1AQ53; Q9BRW4
Background:
Chymotrypsin-like elastase family member 3A, known alternatively as Elastase IIIA, Elastase-3A, and Protease E, is characterized by its efficient protease activity with a preference for alanine. Despite its name, it exhibits limited elastolytic activity, distinguishing it from other elastases in its family.
Therapeutic significance:
Understanding the role of Chymotrypsin-like elastase family member 3A could open doors to potential therapeutic strategies. Its unique substrate specificity suggests it could be a target for designing novel inhibitors or activators to modulate its activity in disease contexts.